Comparative Resistance to Teriparatide-Induced Bone Resorption With Denosumab or Alendronate

CONTEXT: In postmenopausal osteoporotic women, denosumab fully inhibits teriparatide-induced bone resorption at approved doses. This property of denosumab is distinct from that of alendronate and likely contributes to the efficacy of combination denosumab and teriparatide therapy. Whether denosumab...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Clin Endocrinol Metab
Prif Awduron: Tsai, Joy N., Zhu, Yuli, Foley, Katelyn, Lee, Hang, Burnett-Bowie, Sherri-Ann, Neer, Robert M., Leder, Benjamin Z.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Endocrine Society 2015
Pynciau:
Original Articles
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5393530/
https://ncbi.nlm.nih.gov/pubmed/25933031
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jc.2015-1541
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg